Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457390 | 0.86 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Bromide SCHEMBL10598951 | 0.84 | OPRD1 (0.59) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Hydrochloric Acid SCHEMBL7647391 | 0.84 | OPRD1 (0.59) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Trifluoroacetic Acid SCHEMBL21381796 | 0.83 | CES1 (0.47) | OPRD1OPRM1OPRK1KCNH2CES1 | |
| SCHEMBL3663243 | 0.82 | OPRD1 (0.54) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL5845523 | 0.80 | OPRD1 (0.61) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| SCHEMBL8314711 | 0.79 | OPRD1 (0.58) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Trifluoroacetic Acid SCHEMBL5451230 | 0.79 | HTR2C (0.61) | CES1HTR2AHTR2B | |
| SCHEMBL10461671 | 0.78 | OPRM1 (0.67) | OPRD1OPRM1OPRK1KCNH2ABCB11 | |
| Trifluoroacetic Acid SCHEMBL21381795 | 0.78 | OPRD1 (0.62) | OPRD1OPRM1OPRK1KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | NORTHEASTERN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170247387-A1 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2016014975-A2 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | OPRD1 309/4885OPRM1 431/4885OPRK1 354/4885 |
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | FAAH, FAAH2, MGLL | OPRD1 850/4885OPRM1 325/4885OPRK1 674/4885 |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | FAAH, FAAH2, MGLL | OPRD1 364/4885OPRM1 138/4885OPRK1 199/4885 |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | OPRD1 4292/4885OPRM1 3382/4885OPRK1 3247/4885 |
| US-20170247387-A1 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | FAAH, FAAH2, MGLL | OPRD1 1205/4885OPRM1 332/4885OPRK1 961/4885 |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | FAAH, MGLL, FAAH2 | OPRD1 1927/4885OPRM1 552/4885OPRK1 1562/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | OPRD1 4292/4885OPRM1 3382/4885OPRK1 3247/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | OPRD1 4292/4885OPRM1 3382/4885OPRK1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.